Participants were patients with the following diagnoses: giant cell arteritis or Takayasu arteritis, or other types of LVV (isolated aortitis or IgG4-related disease with vasculitis). |
SLR 1: Diagnosis, prognosis and monitoring
|
SLR 2: Drug and surgical treatment
|
Diagnosis: recognition, referral criteria, fast-track diagnosis, role of imaging for diagnosis, role of biopsy for diagnosis, interdisciplinary workup, considerations for subtypes of disease such as cranial/ischaemic/large vessel, isolated aortitis, IgG4related disease, LVV disease in other vasculitides. Prognostic and therapeutic implications of disease phenotypes: cranial versus extracranial, isolated aortitis, other forms including IgG4-related disease, imaging, other biomarkers, comorbidities and complications, disease damage versus activity. Long-term follow-up of patients: clinical assessments and frequency, imaging, patient-reported outcomes, physical therapies and management of complications. Patient education and other aspects of patients-centred care.
|
Drug therapy: dosing, length of therapy, outcome and treatment-related side effects for the following drugs: glucocorticoids, methotrexate and other non-biological immunosuppressive agents (csDMARDs), tocilizumab and other biological DMARDs (bDMARDs). Specific treatment of organ complications: loss of vision and stroke), relapsing, refractory, glucocorticoid-dependent disease. Revascularisation procedures: indications for referral, management of aneurysms and/or vessel stenosis. Adjunctive therapies and prophylaxis: aspirin, cardiovascular and cerebrovascular disease, infections, vaccination, osteoporosis.
|